News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
621,403 Results
Type
Article (36827)
Company Profile (115)
Press Release (584461)
Multimedia
Podcasts (42)
Webinars (7)
Section
Business (172310)
Career Advice (2751)
Deals (32307)
Drug Delivery (87)
Drug Development (72416)
Employer Resources (158)
FDA (15564)
Job Trends (14528)
News (299534)
Policy (28873)
Tag
Academia (2664)
Academic (1)
Accelerated approval (4)
Adcomms (23)
Allergies (92)
Alliances (43180)
ALS (98)
Alzheimer's disease (1419)
Antibody-drug conjugate (ADC) (117)
Approvals (15573)
Artificial intelligence (263)
Autoimmune disease (27)
Automation (15)
Bankruptcy (288)
Best Places to Work (12092)
BIOSECURE Act (17)
Biosimilars (98)
Biotechnology (83)
Bladder cancer (79)
Brain cancer (26)
Breast cancer (290)
Cancer (2276)
Cardiovascular disease (176)
Career advice (2282)
Career pathing (31)
CAR-T (155)
Cell therapy (444)
Cervical cancer (19)
Clinical research (59287)
Collaboration (857)
Company closure (1)
Compensation (562)
Complete response letters (19)
COVID-19 (2464)
CRISPR (44)
C-suite (262)
Cystic fibrosis (105)
Data (2330)
Decentralized trials (1)
Denatured (8)
Depression (42)
Diabetes (266)
Diagnostics (6615)
Digital health (17)
Diversity (3)
Diversity, equity & inclusion (38)
Drug discovery (116)
Drug pricing (90)
Drug shortages (19)
Duchenne muscular dystrophy (93)
Earnings (68621)
Editorial (41)
Employer branding (21)
Employer resources (138)
Events (102634)
Executive appointments (771)
FDA (16937)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (766)
Gene editing (113)
Generative AI (20)
Gene therapy (319)
GLP-1 (612)
Government (4047)
Grass and pollen (5)
Guidances (145)
Healthcare (19833)
Huntington's disease (22)
IgA nephropathy (26)
Immunology and inflammation (111)
Indications (30)
Infectious disease (2607)
Inflammatory bowel disease (148)
Inflation Reduction Act (9)
Influenza (53)
Intellectual property (102)
Interviews (543)
IPO (16177)
IRA (32)
Job creations (2866)
Job search strategy (1891)
Kidney cancer (11)
Labor market (31)
Layoffs (432)
Leadership (23)
Legal (6361)
Liver cancer (67)
Lung cancer (305)
Lymphoma (146)
Machine learning (9)
Management (59)
Manufacturing (311)
MASH (74)
Medical device (14005)
Medtech (14010)
Mergers & acquisitions (16792)
Metabolic disorders (629)
Multiple sclerosis (79)
NASH (13)
Neurodegenerative disease (99)
Neuropsychiatric disorders (24)
Neuroscience (1972)
NextGen: Class of 2025 (6709)
Non-profit (4826)
Now hiring (29)
Obesity (304)
Opinion (226)
Ovarian cancer (81)
Pain (101)
Pancreatic cancer (85)
Parkinson's disease (159)
Partnered (20)
Patents (240)
Patient recruitment (117)
Peanut (49)
People (51664)
Pharmaceutical (33)
Pharmacy benefit managers (19)
Phase I (18478)
Phase II (26325)
Phase III (19622)
Pipeline (1334)
Policy (128)
Postmarket research (2017)
Preclinical (7584)
Press Release (62)
Prostate cancer (103)
Psychedelics (30)
Radiopharmaceuticals (256)
Rare diseases (394)
Real estate (4890)
Recruiting (63)
Regulatory (20534)
Reports (27)
Research institute (2439)
Resumes & cover letters (449)
Rett syndrome (5)
RNA editing (4)
RSV (43)
Schizophrenia (72)
Series A (124)
Series B (88)
Service/supplier (6)
Sickle cell disease (58)
Special edition (13)
Spinal muscular atrophy (146)
Sponsored (25)
Startups (3032)
State (2)
Stomach cancer (7)
Supply chain (66)
Tariffs (41)
The Weekly (33)
Vaccines (641)
Venture capitalists (34)
Weight loss (173)
Women's health (26)
Worklife (18)
Date
Last 7 days (959)
Last 30 days (3081)
Last 365 days (32998)
2025 (12038)
2024 (35954)
2023 (41286)
2022 (52115)
2021 (57040)
2020 (55564)
2019 (48731)
2018 (36629)
2017 (32101)
2016 (30368)
2015 (35472)
2014 (24629)
2013 (19205)
2012 (20726)
2011 (21532)
2010 (18623)
Location
Africa (758)
Alabama (59)
Alaska (7)
Arizona (159)
Arkansas (12)
Asia (36194)
Australia (6450)
California (6449)
Canada (2075)
China (534)
Colorado (278)
Connecticut (292)
Delaware (159)
Europe (83875)
Florida (965)
Georgia (224)
Idaho (58)
Illinois (559)
India (23)
Indiana (324)
Iowa (10)
Japan (168)
Kansas (104)
Kentucky (27)
Louisiana (11)
Maine (70)
Maryland (917)
Massachusetts (4915)
Michigan (245)
Minnesota (407)
Mississippi (2)
Missouri (89)
Montana (31)
Nebraska (25)
Nevada (68)
New Hampshire (68)
New Jersey (1817)
New Mexico (30)
New York (1820)
North Carolina (1049)
North Dakota (9)
Northern California (2853)
Ohio (216)
Oklahoma (14)
Oregon (35)
Pennsylvania (1437)
Puerto Rico (13)
Rhode Island (34)
South America (1082)
South Carolina (25)
South Dakota (1)
Southern California (2456)
Tennessee (107)
Texas (953)
United States (24398)
Utah (199)
Virginia (157)
Washington D.C. (62)
Washington State (579)
West Virginia (3)
Wisconsin (62)
621,403 Results for "oncopeptides ab".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia
April 23, 2025
·
7 min read
Business
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq.
March 27, 2024
·
4 min read
Press Releases
BioInvent International AB: Interim Report January - March 2025
April 29, 2025
·
2 min read
Press Releases
Bulletin from the Annual General Meeting of Vicore Pharma Holding AB (publ)
May 7, 2025
·
4 min read
Press Releases
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
April 28, 2025
·
6 min read
Press Releases
Notice to Annual General Meeting in AlzeCure Pharma AB
April 9, 2025
·
9 min read
Press Releases
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025
May 8, 2025
·
5 min read
Press Releases
Bulletin from the Annual General Meeting in Alligator Bioscience AB on 7 May 2025
May 7, 2025
·
4 min read
Press Releases
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
April 23, 2025
·
7 min read
Press Releases
AB Science will publish its 2024 annual financial report on May 9, 2025
May 1, 2025
·
2 min read
1 of 62,141
Next
